Vaxart, Inc. (VXRT) stock
VXRTOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.48+0.02 (+5.04%)
Close on Oct 19, 2026Market cap $115.61MP/E 4.0Yield –
Vaxart cash
Cash and short-term investments held at the end of each period.
Vaxart's cash was $65.50M at Sep 30, 2026. For fiscal 2025 it was $63.80M, up 23.4% from the year before. Over ten years it grew -2.4% a year on average. The highest annual figure on record is $166.49M in fiscal 2021.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $63.80M | +23.4% |
| FY2024 | Dec 31, 2024 | $51.70M | +30.2% |
| FY2023 | Dec 31, 2023 | $39.70M | -58.5% |
| FY2022 | Dec 31, 2022 | $95.70M | -42.5% |
| FY2021 | Dec 31, 2021 | $166.49M | +31.2% |
| FY2020 | Dec 31, 2020 | $126.87M | +838.0% |
| FY2019 | Dec 31, 2019 | $13.53M | +17.6% |
| FY2018 | Dec 31, 2018 | $11.51M | -83.3% |
| FY2016 | Jun 30, 2016 | $69.00M | +19.8% |
| FY2015 | Jun 30, 2015 | $57.60M | -29.5% |
| FY2014 | Jun 30, 2014 | $81.70M | +22.3% |
| FY2013 | Jun 30, 2013 | $66.80M | +24.2% |
| FY2012 | Jun 30, 2012 | $53.80M | -9.6% |
| FY2009 | Dec 26, 2009 | $59.51M | -44.1% |
| FY2008 | Dec 27, 2008 | $106.44M | – |
Quarterly cash
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ3 2026 | Sep 30, 2026 | $65.50M | +127.4% |
| Q2 FY2026CQ2 2026 | Jun 30, 2026 | $64.00M | +143.3% |
| Q1 FY2026CQ1 2026 | Mar 31, 2026 | $61.00M | +45.6% |
| Q4 FY2025CQ4 2025 | Dec 31, 2025 | $63.80M | +23.4% |
| Q3 FY2025CQ3 2025 | Sep 30, 2025 | $28.80M | -50.9% |
| Q2 FY2025CQ2 2025 | Jun 30, 2025 | $26.30M | -58.0% |
| Q1 FY2025CQ1 2025 | Mar 31, 2025 | $41.90M | +14.2% |
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | $51.70M | +30.2% |
| Q3 FY2024CQ3 2024 | Sep 30, 2024 | $58.70M | +10.8% |
| Q2 FY2024CQ2 2024 | Jun 30, 2024 | $62.60M | -7.8% |
| Q1 FY2024CQ1 2024 | Mar 31, 2024 | $36.70M | -48.9% |
| Q4 FY2023CQ4 2023 | Dec 31, 2023 | $39.70M | -58.5% |
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | $53.00M | -53.8% |
| Q2 FY2023CQ2 2023 | Jun 30, 2023 | $67.90M | -47.6% |
| Q1 FY2023CQ1 2023 | Mar 31, 2023 | $71.80M | -51.4% |
| Q4 FY2022CQ4 2022 | Dec 31, 2022 | $95.70M | -42.5% |
| Q3 FY2022CQ3 2022 | Sep 30, 2022 | $114.77M | -38.8% |
| Q2 FY2022CQ2 2022 | Jun 30, 2022 | $129.55M | -29.8% |
| Q1 FY2022CQ1 2022 | Mar 31, 2022 | $147.66M | -13.5% |
| Q4 FY2021CQ4 2021 | Dec 31, 2021 | $166.49M | +31.2% |
| Q3 FY2021CQ3 2021 | Sep 30, 2021 | $187.67M | +461.3% |
| Q2 FY2021CQ2 2021 | Jun 30, 2021 | $184.58M | +315.8% |
| Q1 FY2021CQ1 2021 | Mar 31, 2021 | $170.70M | +471.7% |
| Q4 FY2020CQ4 2020 | Dec 31, 2020 | $126.87M | +838.0% |
| Q3 FY2020CQ3 2020 | Sep 30, 2020 | $33.44M | +71.0% |
| Q2 FY2020CQ2 2020 | Jun 30, 2020 | $44.39M | +173.0% |
| Q1 FY2020CQ1 2020 | Mar 31, 2020 | $29.86M | +254.5% |
| Q4 FY2019CQ4 2019 | Dec 31, 2019 | $13.53M | +17.6% |
| Q3 FY2019CQ3 2019 | Sep 30, 2019 | $19.56M | +9.1% |
| Q2 FY2019CQ2 2019 | Jun 30, 2019 | $16.26M | -32.0% |
| Q1 FY2019CQ1 2019 | Mar 31, 2019 | $8.42M | -51.8% |
| Q4 FY2018CQ4 2018 | Dec 31, 2018 | $11.51M | -83.3% |
| Q3 FY2018CQ3 2018 | Sep 30, 2018 | $17.92M | -63.4% |
| Q2 FY2018CQ2 2018 | Jun 30, 2018 | $23.92M | -54.0% |
| Q1 FY2018CQ1 2018 | Mar 31, 2018 | $17.50M | -69.4% |
| Q4 FY2016CQ2 2016 | Jun 30, 2016 | $69.00M | +19.8% |
| Q3 FY2016CQ1 2016 | Mar 31, 2016 | $49.00M | – |
| Q2 FY2016CQ4 2015 | Dec 31, 2015 | $52.00M | – |
| Q1 FY2016CQ3 2015 | Sep 30, 2015 | $57.20M | – |
| Q4 FY2015CQ2 2015 | Jun 30, 2015 | $57.60M | – |
See a number that looks wrong?